Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia

Psychoneuroendocrinology

Volumn 28, Issue 3, 2003, Pages 419-445

  Anderer, Peter ^a   Semlitsch, Heribert V ^a   Saletu, Bernd ^a   Saletu Zyhlarz, Gerda ^a   Gruber, Doris ^a   Metka, Markus ^a   Huber, Johannes ^a   Gräser, Thomas ^b   Oettel, Michael ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b BAYER PHARMA AG   (Germany)

Author keywords

Climodien; Estrogen; Event related potential mapping; Hormone replacement therapy; Lafamme; Progestin

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE; ESTRADIOL VALERATE; LAFAMME; PLACEBO;

ADULT; AGED; ARTICLE; ATTENTION; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROENCEPHALOGRAM; ESTROGEN ACTIVITY; EVOKED AUDITORY RESPONSE; FEMALE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; INSOMNIA; LATENT PERIOD; MENOPAUSAL SYNDROME; MENOPAUSE; OPEN STUDY; ORIENTATION; PERCEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0037388995     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(02)00032-X     Document Type: Article

References (167)

1. Abt K. Planning controlled clinical trials on the basis of Descriptive Data Analysis. Stat Med. 10:1991;777-795.
2. Albert M.S., Wolfe J., Lafleche G. Differences in abstraction ability with age. Psychol Aging. 5:1990;94-100.
3. Almeida O.P. Sex playing with the mind. Effects of oestrogen and testosterone on mood and cognition. Arq Neurpsiquiatr. 57:1999;701-706.
4. Anderer P., Semlitsch H.V., Saletu B., Barbanoj M.J. Artifact processing in topographic mapping of EEG in neuropsychopharmacology. Psychiat Res. 45:1992;79-93.
5. Anderer P., Saletu B., Klöppel B., Semlitsch H.V., Werner H. Discrimination between demented patients and normals based on topographic EEG slow wave activity: comparison between z-statistics, discriminant analysis and artificial neural network classifiers. Electroenceph. Clin. Neurophysiol. 91:1994;108-117.
6. Anderer P., Semlitsch H.V., Saletu B. Multichannel auditory event-related potentials: effects of normal aging on the scalp distribution of N1, P2, N2, and P300 latencies and amplitudes. Electroenceph. Clin. Neurophysiol. 99:1996;458-472.
7. Anderer P., Saletu B., Semlitsch H.V., Pascual-Marqui R.D. Electrical sources of P300 event-related potentials revealed by low resolution brain electromagnetic tomopgraphy. 2. Effects of nootropic therapy in age-associated memory impairment. Neuropsychobiology. 37:1998;28-35.
8. Anderer P., Pascual-Marqui R.D., Semlitsch H.V., Saletu B. Differential effects of normal aging on sources of standard N1 and target P300 auditory event-related potentials revealed by low resolution brain electromagnetic tomography (LORETA). Electroenceph. Clin Neurophysiol. 108:1998;160-174.
9. Anderer P., Semlitsch H.V., Eberstaller M., Saletu B., Pfundner P. A robust and valid artifact minimization and identification procedure for 'cognitive' event-related brain potentials. Med. Biol. Eng. Comput. 27:(Suppl. 2):1999;486-487.
10. Anderer P., Saletu B., Pascual-Marqui R.D., Semlitsch H.V. EEG and ERP topography and tomography in normal aging. Saletu B., Krijzer F., Ferber G., Anderer P. Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields - An Update. 2000;122-138 Facultas Universitätsverlag, Vienna.
11. Asthana S., Craft S., Baker L.D., Raskind M.A., Birnbaum R.S., Lofgreen C.P., Veith R.C., Plymate S.R. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology. 24:1999;657-677.
12. Belleville S., Rouleau N., Caza N. Effect of normal aging on the manipulation of information in working memory. Mem Cognit. 26:1998;572-583.
13. Bethea C.L., Pecins-Thompson M., Schutzer W.E., Gundlah C., Lu Z.N. Ovarian steroids and serotonin neural function. Mol Neurobiol. 18:1998;87-123.
14. Bethea, C.L., Gundlah, C., Mirkes, S.J., 2000. Ovarian steroid action in the serotonin neural system of macaques. Novartis Found. Symposium, pp. 230,112-230,130.
15. Bi R., Broutman G., Foy M.R., Thompson R.F., Baudry M. The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc Natl Acad Sci USA. 97:2000;3602-3607.
16. Birzniece V., Johansson I.M., Wang M.D., Seckl J.R., Backstrom T., Olsson T. Serotonin 5-HT(1A) receptor mRNA expression in dorsal hippocampus and ralphe nuclei after gondal hormone manipulation in female rats. Neuroendocrinology. 74:2001;135-142.
17. Bixo M., Bäckström T., Winblad B., Andersson A. Estradiol and testosterone in specific regions of the human female brain in different endocrine states. J. Steroid Biochem. Mol. Biol. 55:1995;297-303.
18. Brinton R.D., Chen S., Montoya M., Hsieh D., Minaya J. The estrogen replacement therapy of the Women's Health Initiative promotes the cellular mechanisms of memory and neuronal survival in neurons vulnerable to Alzheimer's disease. Maturitas. 34:(Suppl. 2):2000;35-52.
19. Carlson L.E., Sherwin B.B. Steroid hormones, memory and mood in a healthy elderly population. Psychoneuroendocrinology. 23:1998;583-602.
20. Caruso S., Cianci A., Grasso D., Agnello C., Galvani F., Maiolino L., Serrs A. Auditory brainstem response in postmenopausal women treated with hormone replacement therapy: a pilot study. Menopause. 7:2000;178-183.
21. Cassel J.C., Jeltsch H. Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience. 69:1995;1-41.
22. Costa M.M., Reus V.I., Wolkowitz O.M., Menfredi F., Lieberman M. Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women. Biol Psychiat. 46:1999;182-188.
23. Coull J.T. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog. Neurobiol. 55:1998;343-361.
24. Crossley M., Hiscock M. Age-related differences in concurrent-task performance of normal adults: evidence for a decline in processing resources. Psychol Aging. 7:1992;499-506.
25. Daigneault S., Braun C.M.J. Working memory and the self-ordered pointing task: further evidence of early prefrontal decline in normal aging. J. Clin. Exp. Neuropsychol. 15:1993;881-895.
26. Dickerson A.E., Fisher A.G. Age differences in functional performance. Am J. Occup. Ther. 47:1993;686-692.
27. Dierks T., Frölich L., Ihl R., Maurer K. Event-related potentials and psychopharmacology. Cholinergic modulation of P300. Pharmacopsychiatry. 27:1994;72-74.
28. Donchin E., Coles M.G.H. Is the P300 component a manifestation of context updating? Brain Behav Sci. 11:1988;357-374.
29. Drake E.B., Henderson V.W., Stanczyk F.Z., McCleary C.A., Brown W.S., Smith C.A., Rizzo A.A., Murdock G.A., Buckwalter J.G. Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology. 54:2000;599-603.
30. Duff S.J., Hampson E. A beneficial effect of estrogen on working memory in postmenopausal women taking hormone replacement therapy. Horm Behav. 38:2000;262-276.
31. Duffy F.H., Albert M.S., McAnulty G., Gravey A. Age-related differences in brain electrical activity of healthy subjects. Ann Neurol. 16:1984;430-438.
32. Duka T., Tasker R., McGowan J.F. The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females. Psychopharmacology. 149:2000;129-139.
33. Dustman R.E., Shearer D.E., Emmerson R.Y. EEG and event-related potentials in normal aging. Prog Neurobiol. 41:1993;369-401.
34. Fedor-Freyberg P. The influence of estrogens on the well-being and mental performance in the climacteric and postmenopausal women. Acta Obstet. Gynecol Scand. 64:1977;12-20.
35. Ferber G., Abt K., Fichte K., Luthringer R. IPEG guideline on statistical design and analysis for pharmacodynamic trials. Neuropsychobiology. 39:1999;92-100.
36. Fillit, H., 1994. Estrogens in the pathogenesis and treatment of Alzheimer's disease in postmenopausal women. Ann. NY Acad. Sci. 743, 233-238.
37. Ford J.M., Roth W.T., Isaacks B.G., Trinklenberg J.R., Yesavage J., Pfefferbaum A. Automatic and effortful processing in aging and dementia: event-related brain potentials. Neurobiol Aging. 18:1997;169-180.
38. Frith C., Dolan R. The role of the prefrontal cortex in higer cognitive functions. Cogn Brain Res. 5:1996;175-181.
39. Frodl-Bauch T., Bottlender R., Hegerl U. Neurochemical substrates and neuroanatomical generators of the event-related P300. Neuropsychobiology. 40:1999;84-94.
40. Genazzani A.R., Spinetti A., Gallo R., Bernardi F. Menopause and the central nervous system: intervention options. Maturitas. 31:1999;103-110.
41. Gibbs R.B. Estrogen and nerve growth factor-related systems in brain. Effects on basal forebrain cholinergic neurons and implications for learning and memory processes and aging. Ann NY Acad Sci. 743:1994;165-196.
42. Gibbs, R.B., 2000. Oestrogen and the cholinergic hypothesis: implications for oestrogen replacement therapy in postmenopausal women. Novartis Found. Symp. 23094-23107.
43. Gibbs R.B., Aggarwal P. Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline. Horm Behav. 34:1998;98-111.
44. Gibbs R.B., Burke A.M., Johnson D.A. Estrogen replacement attenuates effects of scopolamine and lorazepam on memory acquisition and retention. Horm Behav. 34:1998;112-125.
45. Goodin D.S. Clinical utility of long latency 'cognitive' event-related potentials P300: the pros. Electroenceph. Clin Neurophysiol. 76:1990;2-5.
46. Goodin D.S., Squires K.C., Starr A. Long latency event-related components of the auditory evoked potential in dementia. Brain. 101:1978;635-648.
47. Goodin D.S., Squires K.C., Henderson B., Starr A. Age-related variations in evoked potentials to auditory stimuli in normal human subjects. Electroenceph. Clin Neurophysiol. 44:1978;447-458.
48. Grady C.L. Brain imaging and age-related changes in cognition. Exp Gerontol. 33:1998;661-673.
49. Gräser T., Müller A., Mellinger U., Mück A.O., Lippert T.H., Oettel M. Continous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - a dose ranging study. Maturitas. 35:2000;253-265.
50. Gräser T., Koytchev R., Müller A., Oettel M. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest® for continuous combined hormone replacement therapy in postmenopausal women. Climacteric. 3:2000;109-118.
51. ® a new oral preparation for continuous combined hormone replacement therapy in postmenopausal women. Drugs Today. 37:(Suppl. G):2001;17-27.
52. Grodstein F., Chen J., Pollen D.A., Albert M.S., Wilson R.S., Folstein M.F., Evans D.A., Stampfer M.J. Postmenopausal hormone therapy and cognitive function in healthy older women. J. Am. Geriatr. Soc. 48:2000;746-752.
53. Halgren E., Marinkovic K., Chauvel P. Generators of the late cognitive potentials in auditory and visual oddball tasks. Electroenceph. Clin Neurophysiol. 106:1998;156-164.
54. Hammond E.J., Meador K.J., Aung-Din R., Wilder B.J. Cholinergic modulation of human P3 event-related potentials. Neurology. 37:1987;346-350.
55. Haskell S.G., Richardson E.D., Horwitz R.I. The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. J. Clin. Epidemiol. 50:1997;1249-1264.
56. Hazlett E.A., Buchsbaum M.S., Mohs R.C., Spiegel-Cohen J., Wei T.-C., Azueta R., Haznedar M.M., Singer M.B., Shihabuddin L., Luu-Hsia C., Harvey P.D. Age-related shift in brain region activity during successful memory performance. Neurobiol Aging. 19:1998;437-445.
57. Head H. The conception of nervous and mental energy. II. Vigilance: a physiological state of the nervous system. Br J. Psychol. 14:1923;125-147.
58. Henderson V.W. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology. 48:(Suppl. 7):1997;27-35.
59. Henderson V.W. Estrogen, cognition, and woman's risk of Alzheimer's disease. Am. J. Med. 103:1997;11-18.
60. Henderson, V.W., 2000. Oestrogens and dementia. Novartis Found. Symp. 230,254-230,265.
61. Henderson V.W., Paganini-Hill A., Emanuel C.K., Dunn M.E., Buckwalter J.G. Estrogen replacement therapy in older women. Comparison between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 51:1994;896-900.
62. Henderson V.W., Watt L., Buckwalter J.G. Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology. 21:1996;421-430.
63. Hirayasu Y., Samura M., Ohta H., Ogura C. Sex effects on rate of change of P300 latency with age. Clin Neurophysiol. 111:2000;187-194.
64. Hogervorst E., Boshuisen M., Riedel W., Willeken C., Jolles I. The effect of hormone replacement therapy on cognitive function in elderly women. Psychoneuroendocrinology. 24:1999;43-68.
65. Ikeda K., Egashira T., Yamashita J., Okoyama S. Effect of vagal autotransplantation and bifemelane hydrochloride on cholinergic markers and event-related potentials in rats with lesions of the nucleus basalis magnocellularis. Brain Res. 688:1995;171-183.
66. Jacobs D.M., Tang M.X., Stern Y., Sano M., Marder K., Bell K.L., Schofield P., Dooneief G., Gurland B., Mayeux R. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 50:1998;368-373.
67. Janke, W., Debus G., 1996. EWL 60 S. In: Collegium Internationale Psychiatriae Scalarum (Ed.), Internationale Skalen für Psychiatrie. Beltz-Test, Göttingen.
68. Kampen D.L., Sherwin B.B. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 83:1994;979-983.
69. Kaneda Y., Ikuta T., Nakayama H., Kagawa K., Furuta N. Visual evoked potentials and electroencephalogram of healthy females during the menstrual cycle. J. Med. Invest. 44:1997;41-46.
70. Kawas C., Resnick S., Morrison A., Brookmeyer R., Corrada M., Zonderman A., Bacal C., Lingle D.D., Metter E. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 48:1997;1517-1521.
71. Kawas C., Gray S., Brookmeyer R., Fozard J., Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 54:2000;2072-2077.
72. Keenan P.A., Ezzat W.H., Ginsburg K., Moore G.J. Prefrontal cortex as the site of estrogen's effect on cognition. Psychoneuroedocrinology. 26:2001;577-590.
73. Kemper T. Neuroanatomical and neuropathological changes in normal aging and dementia. Albert M.L. Clinical Neurology of Aging. 1984;9-52 Oxford University Press, New York.
74. Klaiber E.L., Broverman D.M., Vogel W., Peterson L.G., Snyder M.B. Individual differences in changes in mood and platelet monoamine oxidase (MAO) activity during hormonal replacement therapy in menopausal women. Psychoneuroedocrinology. 21:1996;575-592.
75. Klaiber E.L., Broverman D.M., Vogel W., Peterson L.G., Snyder M.B. Relationships of serum estradiol levels, menopausal duration, and mood during hormonal replacement therapy. Psychoneuroendocrinology. 22:1997;549-558.
76. Kluck N., O'Connor S., Hesselbrock V., Tasman A., Maier D., Bauer L. Variation in evoked potential measures over the menstrual cycle: a pilot study. Prog. Neuropsychopharmacol. Biol Psychiat. 16:1992;901-911.
77. Knott V., Bosman M., Mahoney C., Ilivitsky V., Quirt K. Transdermal nicotine: single dose effects on mood, EEG, performance, and event-related potentials. Pharmacol. Biochem. Behav. 63:1999;253-261.
78. Kok A. Event-related potential (ERP) reflections of mental resources: a review and synthesis. Biol Psychol. 45:1997;19-56.
79. Kritzer M.F., Kohama S.G. Ovarian hormones differentially influence immunoreactivity for dopamine beta-hydroxylase, choline acetyltransferase, and serotonin in the dorsolateral prefrontal cortex of adult rhesus monkeys. J. Comp. Neurol. 409:1999;438-451.
80. Kügler C.F.A., Taghavy A., Platt D. The event-related P300 potential analysis of cognitive human brain aging: a review. Gerontology. 39:1993;280-303.
81. Lacin S., Oruc S., Karaca S., Kuscu K., Koyuncu F., Uyar Y., Caglar H. Assessment of the effectiveness of postmenopausal tibolone therapy on neural functions by measuring visual evoked potentials: a placebo-controlled study. Eur J. Obstet. Gynecol. Reprod. Biol. 98:2001;72-76.
82. Laux L., Glanzmann P., Schaffner P., Spielberger C.D. Das State Trait Angstinventar. 1981;Beltz Testgesellschaft, Weinheim.
83. LeBlanc E.S., Janowsky J., Chan B.K.S., Nelson H.D. Hormone replacement therapy and cognition. Systematic review and meta-analysis. JAMA. 285:2001;1489-1499.
84. Li C., Samsioe G., Wilaman K., Lidfelt J., Nerbrand C., Agardh C.D., Schersten B. Effects of norethisterone acetate addition to estradiol in long term HRT. Maturitas. 36:2000;139-152.
85. Linzmayer L., Semlitsch H.V., Saletu B., Böck G., Saletu-Zyhlarz G., Zoghlami A., Gruber D., Metka M., Huber J., Oettel M., Gräser T., Grünberger J. Double-blind placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneim. Forsch. Drug. Res. 51:2001;238-245.
86. Lopez-Jaramillo P., Teran E. Improvement in functions of the cerebral nervous system by estrogen replacement therapy might be related with an increased nitric oxide production. Endothelium. 6:1999;263-266.
87. Lu N.Z., Shlaes T.A., Gundlah C., Dziennis S.E., Lyle R.E., Bethea C.L. Ovarian steroid action on tryptophan hydroxylase protein and serotonin compared to localization of ovarian steroid receptors in midbrain of guinea pigs. Endocrine. 11:1999;257-267.
88. Maki P.M., Zonderman A.B., Resnick S.M. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J. Psychiat. 158:2001;227-233.
89. Meador K.J., Loring D.W., Adams R.J., Patel B.R., Davis H.C., Hammond E.J. Central cholinergic systems and the P300 evoked potential. Int J. Neurosci. 33:1987;199-205.
90. Meador K.J., Loring D.W., Lee G.P., Taylor H.S., Hughes D.R., Feldman D.S. In vivo probe of central cholinergic systems. J. Gerontol. 43:1988;158-162.
91. Meador K.J., Loring D.W., Davis H.C., Sethi K.D., Patel B.R., Adams R.J., Hammond E.J. Cholinergic and serotonergic effects on the P3 potential and recent memory. J. Clin. Exp. Neuropsychol. 11:1989;252-260.
92. Meador K.J., Loring D.W., Hendrix N., Nichols M.E., Oberzan R., Moore E.E. Synergistic anticholinergic and antiserotonergic effects in humans. J. Clin. Exp. Neurophysiol. 17:1995;611-621.
93. Meltzer C.C., Smith G., DeKosky S.T., Pollock B.G., Mathis C.A., Moore R.Y., Kupfer D.J., Reynolds C.F. Serotonin in aging, late-life depression and Alzheimer's disease: the emerging role of finctional imaging. Neuropsychopharmacology. 18:1998;407-430.
94. Molchan S.E., Martinez R.A., Hill J.L., Weingartner H.J., Thompson K., Vitiello B., Sunderland T. Increased cognitive sensitivity to scopolamine with age and a perspective on scopolamine model. Brain Res Rev. 17:1992;215-226.
95. Moses E.L., Drevets W.-C., Smith G., Mathis C.A., Kalro B.N., Butters M.A., Leondires M.P., Greer P.J., Lopresti B., Loucks T.L., Berga S.L. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiat. 15:2000;854-860.
96. Näätänen R., Picton T. The N1 wave of the human electric and magnetic response to sound: a review and an analysis of the component structure. Psychophysiology. 24:1987;375-425.
97. Natale V., Albertazzi P., Zini M., Di-Micco R. Exploration of cyclical changes in memory and mood in postmenopausal women taking sequential combined oestrogen and progestogen preparations. BJOG. 108:2001;286-290.
98. Nobilio D., Faricelli A., Colangelo U., Delre M.L., Bazzano S., Onofrj M., Gambi D. The effects of levo-acetyl-carnitine on P300 potential. Curr. Ther. Res. Clin Exp. 47:1990;267-277.
99. O'Donnell B.F., Friedman S., Squires N.K., Maloon A., Drachman D., Swearer J. Active and passive P300 latency in dementia. Neuropsychiat Neuropsychol. Behav Neurol. 2:1990;164-169.
100. Oettel M., Carol W., Elger W., Kaufmann G., Moore C., Römer W., Klinger G., Schneider B., Schröder J., Sobek L., Walter F., Zimmermann H. A 19-norprogeston without an ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today. 31:1995;517-536.
101. Oettel M., Gräser T., Hoffmann H. Why dienogest as a progestogenic component of postmenopausal nonandrogenic hormone replacement therapy? Drugs Today. 37:(Suppl. G):2001;3-15.
102. Osawa, M., 1995. P300 and neuropsychological function in normal aging and dementia. Electroenceph. Clin. Neurophysiol. Suppl. 44, 369-376.
103. Paganini-Hill A., Henderson V.W. Estrogen deficiency and risk of Alzheimer's disease in women. Am J. Epidemiol. 140:1994;256-261.
104. Paganini-Hill A., Henderson V.W. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 28:1996;2213-2217.
105. Panay N., Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update. 3:1997;159-171.
106. Pfefferbaum A., Christensen C., Ford J.M., Kopell B.S. Apparent response incompatibility effects on P300 latency depend on task. Electroenceph. Clin Neurophysiol. 64:1986;424-437.
107. Pfefferbaum A., Ford J., Kraemer H.C. Clinical utility of long latency 'cognitive' event-related potentials P300: the cons. Electroenceph. Clin Neurophysiol. 76:1990;6-12.
108. Picton T.W., Stuss D.T., Champagne S.C., Nelson R.F. The effects of age on human event-related potentials. Psychophysiology. 21:1984;312-326.
109. Polich J. P300 in the evaluation of aging and dementia. Brunia C.H.M., Mulder G., Verbaten M.N. Event-Related Brain Research (EEG Suppl. 42). 1991;304-323 Elsevier, Amsterdam.
110. Polich J. Meta-analysis of P300 normative aging studies. Psychophysiology. 33:1996;334-353.
111. Polich J. EEG and ERP assessment of normal aging. Electroenceph. Clin Neurophysiol. 104:1997;224-256.
112. Polich J. P300 clinical utility and control of variability. J. Clin. Neurophysiol. 15:1998;14-33.
113. Polich J., Kok A. Cognitive and biological determinants of P300: an integrative review. Biol Psychol. 41:1995;103-146.
114. Polich J., Ladish C., Burns T. P300 assessment of early Alzheimer's disease. Electroenceph. Clin Neurophysiol. 77:1990;179-189.
115. Portin R., Kavola T., Polo-Kantola P., Revonsuo A., Muller K., Matikainen E. Does P3 reflect attentional or memory performance, or cognition more generally? Scand J. Psychol. 41:2000;31-40.
116. Potter D.D., Pickles C.D., Roberts R.C., Rugg M.D. Scopolamine impairs memory performance and reduces frontal but not parietal visual P3 amplitude. Biol Psychol. 52:2000;37-52.
117. Rasgon N.L., Small G.W., Siddarth P., Miller K., Ercoli L.M., Bookheimer S.Y., Lavertsky H., Huang S.C., Barrio J.R., Phelps M.E. Estrogen use and brain metabolic change in older adults. A preliminary report. Psychiat Res. 107:2001;11-18.
118. Ray P.G., Meador K.J., Loring D.W., Zamrini E.W., Yang X.H., Buccafusco J.J. Central anticholinergic hypersensitivity in aging. J. Geriatr. Psychiatry Neurol. 5:1992;72-77.
119. Rechtschaffen A., Kales A. A Manual of Standardized Terminology. Techniques and Scoring System for Sleep Stages of Human Subjects. 1968;Brain Information Service/Brain Research Institute, University of California, Los Angeles.
120. Resende L.A., Silva M.D., Impemba F., Achoa N.B., Schelp A.O. Multimodal evoked potentials and the ovarian cycle in young ovulating women. Arq Neuropsiquiatr. 58:2000;418-423.
121. Resnick S.M., Metter E.J., Zonderman A.B. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology. 49:1997;1491-1497.
122. Resnick S.M., Maki P.M., Golski S., Kraut M., Zonderman A.B. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav. 34:1998;171-182.
123. Rice M.M., Graves A.B., McCurry S.M., Larson E.B. Estrogen replacement therapy and cognitive function in postmenopausal women without dementia. Am. J. Med. 22:1997;S26-S35.
124. Rice M.M., Graves A.B., McCurry S.M., Gibbons L.E., Bowen J.D., McCormick W.C., Larson E.B. Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese Americal women: The Kame Project. Arch. Intern Med. 160:2000;1641-1649.
125. Robinson D., Friedman L., Marcus R., Trinklenberg J., Yesavage J. Estrogen replacement therapy and memory in older women. J. Am. Geriatr. Soc. 42:1994;919-922.
126. Rodriguez M.M., Grossberg G.T. Estrogen as a psychotherapeutic agent. Clin. Geriatr Med. 14:1998;177-189.
127. Saletu B., Semlitsch H., Anderer P., Resch F., Presslich O., Schuster P. Psychophysiological research in psychiatry and neuropsychopharmacology. II. The investigation of antihypoxidotic/nootropic drugs (tenilsetam and co-dergocrine- mesylate) in elderlies with the Viennese Psychophysiological Test- System) (VPTS). Meth Find. Exp. Clin Pharmacol. 11:1989;43-55.
128. Saletu B., Anderer P., Paulus E., Grünberger J., Wicke L., Neuhold A., Fischhof K.P., Litschauer G. EEG brain mapping in diagnostic and therapeutic assessment of dementia. Alzheimer Dis. Assoc. Disord. 5:(Suppl. 1):1991;57-75.
129. Saletu B., Paulus E., Linzmayer L., Anderer P., Semlitsch H.V., Grünberger J., Wicke L., Neuhold A., Podreka I. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology. 117:1995;385-395.
130. Saletu B., Brandstätter N., Metka M., Stamenkovic M., Anderer P., Semlitsch H.V., Heytmanek G., Huber J., Grünberger J., Linzmayer L., Kurz C., Decker K., Binder G., Knogler W., Koll B. Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Psychopharmacology. 122:1995;321-329.
131. Saletu B., Brandstätter N., Metka M., Stamenkovic M., Anderer P., Semlitsch H.V., Heytmanek G., Huber J., Grünberger J., Linzmayer L., Kurz C., Decker K., Binder G., Knogler W., Koll B. Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls. Maturitas. 23:1996;91-105.
132. Saletu B., Anderer P., Semlitsch H.V. Relations between symptomatology and brain function in dementias: double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline. Dement. Geriatr. Cogn. Disord. 8:(Suppl. 1):1997;12-21.
133. Saletu B., Anderer P., Gruber G., Mandl M., Gruber D., Metka M., Huber J., Abu-Bakr M.H., Saletu-Zyhlarz G.M. Insomnia related to postmenopausal syndrome: sleep laboratory studies on differences between patients and normal controls, and influence of an estrogen-progestogen combination with dienogest versus estrogen alone and placebo. Drugs Today. 37:(Suppl. G):2001;39-62.
134. Saletu, B., Anderer, P., Gruber, D., Metka, M., Huber, J. Saletu-Zyhlarz, G.M., 2002. Hormone replacement therapy and vigilance: double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien®, Lafamme®) versus estrogen alone in menopausal syndrome patients. Maturitas, in press.
135. Sarrel P.M. Hormone replacement therapy in the menopause. Int J. Fertil. Womens Med. 42:1997;78-84.
136. Schmidt R., Fazekas F., Reinhart B., Kapeller P., Fazekas G., Offenbacher H., Eber B., Schumacher M., Freidl W. Estrogen replacement therapy in older women: a neuropsychological and brain MRI study. J. Am. Geriatr. Soc. 44:1996;1307-1313.
137. Schneider L.S., Finch C.E. Can estrogens prevent neurodegeneration? Drugs Aging. 11:1997;87-95.
138. Schneider H.P. The role of antiandrogens in hormone replacement therapy. Climacteric. 3:(Suppl.):2000;221-227.
139. Semlitsch H.V., Anderer P., Schuster P., Presslich O. A solution for reliable and valid reduction of ocular artifacts applied to the P300 ERP. Psychophysiology. 23:1986;695-703.
140. Semlitsch H., Anderer P., Saletu B., Resch F., Presslich O., Schuster P. Psychophysiological research in psychiatry and neuropharmacology. I. Methodological aspects of the Viennese Psychophysiological Test-System (VPTS). Meth. Find. Exp. Clin Pharmacol. 11:1989;25-41.
141. Semlitsch H.V., Anderer P., Saletu B., Hochmayer I. Topographic mapping of cognitive event-related potentials in a double-blind placebo-controlled study with the hemoderivative actovegin in age-associated memory impairment. Neuropsychobiology. 24:1991;49-56.
142. Semlitsch H.V., Anderer P., Saletu B. Topographic mapping of long latency 'cognitive' event-related potentials (P300): a double-blind placebo-controlled study with amantadine in mild dementia. J. Neural Transm. Park. Dis. Dement. Sect. 4:1992;319-336.
143. Semlitsch H.V., Anderer P., Saletu B., Binder G.A., Decker K.A. Cognitive psychophysiology in nootropic drug research: effects of ginkgo biloba on event-related potentials (P300) in age-associated memory impairment. Pharmacopsychiatry. 28:1995;134-142.
144. Semlitsch H.V., Saletu B., Anderer P., Grünberger J., Linzmayer L. Testing drugs for impaired brain function in old age: on the effects of a single dose of bifemelane using topographic mapping of EEG and event-related potentials (P300) and psychometric measurements in healthy elderly subjects. Hum Psychopharmacol. 11:1996;379-390.
145. Shepherd J.E. Effects of estrogen on cognition, mood, and degenerative brain diseases. J. Am. Pharm. Assoc. (Wash). 41:2001;221-228.
146. Sherwin B.B. Estrogen effects on cognition in menopausal women. Neurology. 48:(Suppl. 7):1997;S21-S26.
147. Sherwin B.B. Cognitive assessment for postmenopausal women and general assessment of their mental health. Psychopharmacol Bull. 34:1998;323-326.
148. Skoog I., Gustafson D. HRT and dementia. J. Epidemiol. Biostat. 4:1999;227-251.
149. Skouby S.O. The rationale for a wider range of progestogens. Climacteric. 3:(Suppl. 2):2000;14-20.
150. Smith C.A., McCleary C.A., Murdock G.A., Wilshire T.W., Buckwalter D.K., Bretsky P., Marmol L., Gorsuch R.L., Buckwalter J.G. Lifelong estrogen exposure and cognitive performance in elderly women. Brain Cogn. 39:1999;203-218.
151. Smith M.C. Neurophysiology of aging. Semin Neurol. 9:1989;68-81.
152. Smith Y.R., Minoshima S., Kuhl D.E., Zubieta J.-K. Effects of long-term hormone therapy on cholinergic synaptic concentrations in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 86:2001;679-684.
153. Souchay C., Isingrini M., Espagnet L. Aging, episodic memory feeling-of knowing, and frontal functioning. Neuropsychology. 14:2000;299-309.
154. Squires N.K., Squires K.C., Hillyard S.A. Two varieties of long-latency positive waves evoked by unpredictable auditory stimuli in man. Electroenceph. Clin Neurophysiol. 38:1975;387-401.
155. Steffens D.C., Norton M.C., Plassman B.L., Tschanz J.T., Wyse B.W., Welsh-Bohmer K.A., Anthony J.C., Breitner J.C. Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women. J. Am. Geriatr. Soc. 47:1999;1171-1175.
156. Sweeney J.A., Rosano C., Berman R.A., Luna B. Inhibitory control of attention declines more than working memory during normal aging. Neurobiol Aging. 22:2001;39-47.
157. Toran-Allerand, C.D., 2000. Novel sites and mechanisms of oestrogen action in the brain. Novartis Found. Symp. 23,056-23,069.
158. Toran-Allerand C.D., Miranda R.C., Bentham W.D., Sohrabji F., Brown T.J., Hochberg R.B., MacLusky N.J. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci. USA. 89:1992;4668-4672.
159. van Amelsvoort T.A., Abel K.M., Robertson D.M., Daly E., Critchley H., Whitehead M., Murphy D.G. Prolactin response to d-fenfluramine in postmenopausal women on and off ERT: comparison with young women. Psychoneuroendocrinology. 26:2001;493-502.
160. von Zerssen D. Die Beschwerdenliste (list of complaints) als Test. Therapiewoche. 2:1971;1908-1914.
161. Wolf O.T., Kudielka B.M., Hellhammer D.H., Torber S., McEwen B.S., Kirschbaum C. Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: verbal memory changes are associated with the treatment induced estradiol levels. Psychoneuroendocrinology. 24:1999;727-741.
162. Whooley M.A., Grady D., Cauley J.A. Postmenopausal estrogen therapy and depressive symptoms in older women. J. Gen. Intern. Med. 15:2000;535-541.
163. Yaffe K., Sawaya G., Lieberburg I., Grady D. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA. 279:1998;688-695.
164. Yaffe K., Browner W., Cauley J., Launer L., Harris T. Association between bone mineral density and cognitive decline in older women. J. Am. Geriatr. Soc. 47:1999;1176-1182.
165. Yaffe K., Lui L.Y., Grady D., Cauley J., Kramer J., Cummings S.R. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet. 356:2000;708-712.
166. Yilmaz H., Erkin E., Mavioglu H., Lacin S. Effects of oestrogen replacement therapy on pattern reversal visual evoked potentials. Eur J. Neurol. 7:2000;217-221.
167. Zweifel J.E., O'Brien W.H. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 22:1997;189-212.